X-108606883-G-C
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PS1_ModeratePM2PP3_StrongPP5_Moderate
The NM_033380.3(COL4A5):c.2386G>C(p.Gly796Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★). Another nucleotide change resulting in same amino acid change has been previously reported as Likely pathogenicin UniProt.
Frequency
Consequence
NM_033380.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COL4A5 | NM_033380.3 | c.2386G>C | p.Gly796Arg | missense_variant | 29/53 | ENST00000328300.11 | NP_203699.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COL4A5 | ENST00000328300.11 | c.2386G>C | p.Gly796Arg | missense_variant | 29/53 | 1 | NM_033380.3 | ENSP00000331902 | ||
COL4A5 | ENST00000483338.1 | c.1210G>C | p.Gly404Arg | missense_variant | 13/20 | 1 | ENSP00000495685 | |||
COL4A5 | ENST00000361603.7 | c.2386G>C | p.Gly796Arg | missense_variant | 29/51 | 2 | ENSP00000354505 | P1 |
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 23
ClinVar
Submissions by phenotype
COL4A5-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 21, 2024 | The COL4A5 c.2386G>C variant is predicted to result in the amino acid substitution p.Gly796Arg. This variant was reported in an individual with Alport syndrome or other chronic kidney disease (Lieberman et al. 2022. PubMed ID: 36128480). This variant resides in the triple-helical region (residues 42 – 1456) of the COL4A5 protein (uniprot.org). The majority of pathogenic variants in COL4A5 substitute a glycine residue to a bulkier amino acid in the triple-helical domain (Hudson et al. 1993. PubMed ID: 8253711; https://www.ncbi.nlm.nih.gov/books/NBK1207/). This variant has not been reported in a large population database, indicating this variant is rare. An alternate nucleotide change resulting in the same amino acid change has been reported in a family with Alport syndrome (described as c.2589G>A, G796R, Boye et al. 1995. PubMed ID: 7599631). An alternate nucleotide change affecting the same amino acid (p.Gly796Glu) has been reported in a family with Alport syndrome and an individual with focal segmental glomerulosclerosis and hearing loss (Supplementary table S1, Wang. 2012. PubMed ID: 22921432; table 4, Mallett et al. 2017. PubMed ID: 28844315). This variant is interpreted as pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 06, 2019 | Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL4A5, missense variants at these glycine residues are significantly enriched in individuals with disease (PMID: 23720012, 27627812) compared to the general population (ExAC). For these reasons, this variant has been classified as Pathogenic. This missense change has been observed in individual(s) with Alport syndrome (PMID: 7599631, Invitae). This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with arginine at codon 796 of the COL4A5 protein (p.Gly796Arg). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and arginine. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at